John Newman
Stock Analyst at Canaccord Genuity
(2.05)
# 2,370
Out of 4,479 analysts
46
Total ratings
40.38%
Success rate
-7.91%
Average return
Main Sectors:
Top Industries:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,152 | $1,044.66 | +10.28% | 11 | Jun 27, 2024 | |
| MCRB Seres Therapeutics | Maintains: Buy | $15 → $10 | $0.70 | +1,326.53% | 4 | Jun 7, 2024 | |
| MRUS Merus | Maintains: Buy | $54 → $67 | $53.09 | +26.20% | 1 | Jun 4, 2024 | |
| APTO Aptose Biosciences | Maintains: Buy | $15 → $6 | $0.74 | +707.54% | 1 | May 16, 2024 | |
| OCUP Ocuphire Pharma | Maintains: Buy | $22 → $18 | $1.55 | +1,061.29% | 1 | May 13, 2024 | |
| TSVT 2seventy bio | Maintains: Buy | $12 → $11 | $3.86 | +184.97% | 1 | May 9, 2024 | |
| ACET Adicet Bio | Reiterates: Buy | $19 | $1.10 | +1,627.27% | 4 | Mar 20, 2024 | |
| ACLX Arcellx | Maintains: Buy | $66 → $85 | $53.25 | +59.62% | 6 | Feb 29, 2024 | |
| ONCY Oncolytics Biotech | Reiterates: Buy | $5 | $0.99 | +405.05% | 2 | Jun 23, 2023 | |
| ALLO Allogene Therapeutics | Reiterates: Buy | $35 | $2.16 | +1,520.37% | 1 | Jun 16, 2023 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $50 → $20 | $7.52 | +165.96% | 1 | May 9, 2023 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $52 → $44 | $42.05 | +4.64% | 1 | Feb 16, 2022 | |
| BLUE bluebird bio | Downgrades: Hold | n/a | $0.92 | - | 3 | Aug 10, 2021 | |
| ALRN Aileron Therapeutics | Maintains: Buy | n/a | $2.76 | - | 2 | Apr 9, 2019 | |
| SAGE Sage Therapeutics | Maintains: Buy | n/a | $10.82 | - | 3 | Jun 13, 2018 | |
| VBIV VBI Vaccines | Initiates: Buy | n/a | $0.71 | - | 1 | Nov 1, 2017 | |
| HCM HUTCHMED (China) | Maintains: Buy | n/a | $17.22 | - | 1 | Oct 17, 2017 | |
| ALDX Aldeyra Therapeutics | Maintains: Buy | n/a | $3.25 | - | 1 | Sep 13, 2017 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Speculative Buy | n/a | $5.43 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Jun 27, 2024
Maintains: Buy
Price Target: $1,152
Current: $1,044.66
Upside: +10.28%
Seres Therapeutics
Jun 7, 2024
Maintains: Buy
Price Target: $15 → $10
Current: $0.70
Upside: +1,326.53%
Merus
Jun 4, 2024
Maintains: Buy
Price Target: $54 → $67
Current: $53.09
Upside: +26.20%
Aptose Biosciences
May 16, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.74
Upside: +707.54%
Ocuphire Pharma
May 13, 2024
Maintains: Buy
Price Target: $22 → $18
Current: $1.55
Upside: +1,061.29%
2seventy bio
May 9, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $3.86
Upside: +184.97%
Adicet Bio
Mar 20, 2024
Reiterates: Buy
Price Target: $19
Current: $1.10
Upside: +1,627.27%
Arcellx
Feb 29, 2024
Maintains: Buy
Price Target: $66 → $85
Current: $53.25
Upside: +59.62%
Oncolytics Biotech
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.99
Upside: +405.05%
Allogene Therapeutics
Jun 16, 2023
Reiterates: Buy
Price Target: $35
Current: $2.16
Upside: +1,520.37%
Atara Biotherapeutics
May 9, 2023
Maintains: Buy
Price Target: $50 → $20
Current: $7.52
Upside: +165.96%
Agios Pharmaceuticals
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $42.05
Upside: +4.64%
bluebird bio
Aug 10, 2021
Downgrades: Hold
Price Target: n/a
Current: $0.92
Upside: -
Aileron Therapeutics
Apr 9, 2019
Maintains: Buy
Price Target: n/a
Current: $2.76
Upside: -
Sage Therapeutics
Jun 13, 2018
Maintains: Buy
Price Target: n/a
Current: $10.82
Upside: -
VBI Vaccines
Nov 1, 2017
Initiates: Buy
Price Target: n/a
Current: $0.71
Upside: -
HUTCHMED (China)
Oct 17, 2017
Maintains: Buy
Price Target: n/a
Current: $17.22
Upside: -
Aldeyra Therapeutics
Sep 13, 2017
Maintains: Buy
Price Target: n/a
Current: $3.25
Upside: -
Aurinia Pharmaceuticals
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $5.43
Upside: -